The Latest Cardiac and Vascular News
The upgrade accelerates a health system’s capability to go from reactive to proactive cardiovascular care along guideline-directed treatment pathways ALISO VIEJO, Calif., Sept. 8, 2026 /PRNewswire/ — egnite, Inc., a healthcare AI company focused on helping clinicians identify and manage…
Abbott’s TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) cases Strong clinical evidence demonstrates the device’s high rates of safety and effectiveness…
WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026. Mr. Salmon brings over three decades of global leadership experience in the medical device and pharmaceutical industries, culminating in more than 20 years at Medtronic plc (NYSE: MDT). He most recently served as Executive Vice President and President of its Cardiovascular Portf
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p
– First to demonstrate clinical utility of ring-type BP monitoring in AF and heart failure patients – Highlighted CART blood pressure monitor’s multifaceted value, including ESH-based validation and sleep apnea tracking MUNICH and SEOUL, South Korea, Sept. 7, 2026 /PRNewswire/ — Sky Labs…
First comprehensive systematic review provides insights into the long-term safety profile of angiogenic approaches in coronary artery disease Data shows no evidence of increased cancer or retinopathy, resolving long-standing safety questions that have limited progress across the field…
CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared to placebo. Consistent with previous studies, substan
SOUTH JORDAN, Utah, Sept. 04, 2026 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management is scheduled to participate in the following upcoming investor conferences: The Wells Fargo 2026 Healthcare Conference, which is being held in Boston, MA from September 8-10, 2026. Management is scheduled to participate in a fireside chat on Thursday, September 10th at 8:45 a.m. Eastern Time. The Baird 2026 Global Healthcare Conference, which is being held in New York, NY on September 15, 2026. Management is scheduled to present on Tuesday, September 15th at 8:30 a.m. Eastern Time. The 19th Annual Barrington Research Virtual Fall Investment Conference, which is being held virtually on September 22, 2026. Management is scheduled to participate in 1×1 meetings only, with no formal presentation session. The Sidoti Small Cap Conference, which is being held virtually from September 23-24, 2026. Management is scheduled to participate in 1×1 meetings only on Wednesday, September 23rd, with no formal presentation session. Live audio webcasts of the fireside chats will be accessible under the “Events” section of Merit’s investor relations website at Investor Events and Presentations – Merit Medical. Replays of the fireside chats will be available on this same website for approximately 90 days.ABOUT MERIT MEDICAL Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,500 people worldwide. CONTACTS PR/Media Inquiries Sarah ComstockMerit Medical +1-801-432-2864 | sarah.comstock@merit.com Investor Inquiries Mike Piccinino, CFA, IRC ICR Healthcare +1-443-213-0509 | mike.piccinino@icrhealthcare.com
Following recent U.S. Food and Drug Administration (FDA) labeling approval, European label milestone reinforces Medtronic leadership in advancing aortic care based on clinical evidence supporting the treatment of ruptured abdominal aortic aneurysms (rAAA). Cardiovascular Diagnostics and Services Europe, Middle East & Africa Medtronic plc, a global leader in healthcare technology, […]
LAKE FOREST, Calif.–(BUSINESS WIRE)–SinglePass, Inc., developer of the SinglePass biopsy closure device, today announced the publication of a multicenter (Hoag Health System, Newport Beach and Irvine, California) retrospective clinical data study in the Journal of Vascular and Interventional Radiology (JVIR). Across 120 consecutive patients followed for 30 days, the SinglePass device achieved a 100% technical success rate with zero clinically significant bleeding events.1 Percutaneous biopsy
